Quantcast

Latest rheumatoid arthritis Stories

2014-11-18 08:30:41

PETACH TIKVA, Israel, Nov. 18, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.

2014-11-16 16:21:13

- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies

2014-11-15 16:21:18

- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies EAST HANOVER, N.J., Nov.

2014-11-11 08:29:34

~Data to be presented at the American College of Rheumatology Annual Meeting CHARLOTTESVILLE, Va., Nov.

2014-11-10 08:33:47

Be Joint Smart to educate roughly 48,000 local residents with PsA about their disease PORTLAND, Ore., Nov.

2014-11-10 08:32:16

- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 EAST HANOVER, N.J., Nov.

2014-11-05 16:29:26

VANCOUVER, Nov. 5, 2014 /PRNewswire/ - Augurex Life Sciences Corp.

2014-10-29 16:28:36

Payers Employ a Variety of Cost-Control Measures to Manage the Utilization of Premium-Priced RA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.

2014-10-29 12:30:01

New endurance program unites psoriatic disease community and cycling enthusiasts to find a cure PORTLAND, Ore., Oct.

2014-10-28 23:02:36

Achieve Clinical Research recently opened up a new clinical trial, and they are looking to enroll individuals who are suffering from clinically relevant arthritis pain.


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related